Loading data for AMLX — first visit, this takes a few seconds.

アラート

Amylyx Pharmaceuticals In... (AMLX)

NasdaqGS: AMLX · リアルタイム株価 · USD

35.11

+13.68 (63.84%)

終値時点： Aug 18, 2026, 3:59 PM

63.84% (1D)

買気配	n/a
時価総額	3.91B
売上高（TTM）	n/a
純利益（TTM）	-152.09M
ベータ	-0.20
EPS（TTM）	-2.31
PER（TTM）	n/a
予想PER	-25.33
PBR（TTM）	16.35
PSR（TTM）	n/a
Earnings Date	Nov 5, 2026

売気配	n/a
出来高	23,606,658
平均出来高（20日）	2,043,522
始値	29.93
前日終値	21.43
当日レンジ	28.00 - 35.39
52週レンジ	7.63 - 35.39
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

AMLXについて

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also devel...

[続きを読む]

業種 Drug Manufacturers - Specialty & Generic

セクター Healthcare

IPO日 Jan 7, 2022

従業員数 136

上場取引所 NasdaqGS

ティッカー AMLX

ウェブサイト https://amylyx.com

企業情報の全文

業績

2025年のAmylyx Pharmaceuticalsの売上高は0で、前年の87.37Mから-100%の減少でした。利益は-144.74Mで、-52.03%の減少でした。

財務諸表

決算サプライズ

Amylyx PharmaceuticalsはAug 6, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.39 で、予想を下回りました -0.03, うち 15.22% の前年比増加にあたります.

次回決算発表

Amylyx Pharmaceuticals Inc.の決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

11時間前 · Insider Monkey

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical stu...

11時間前 · Motley Fool

Why Amylyx Pharmaceuticals Stock Skyrocketed Today

GLP-1 drugs aren't just for weight loss.

13時間前 · Stocktwits

AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering

The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.

15時間前 · Barrons.com

Micron, Coherent, SpaceX, Klarna, Amylyx, and More Stocks That Explain Today’s Market

FEATURE Stocks dropped Tuesday, dragged down by pressure on artificial-intelligence infrastructure companies and heightened tensions in the Middle East. Optical network provider Coherent sank 13%, ma...

15時間前 · Investor's Business Daily

A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

2ページ中1ページ